A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 6, 2008, Pages 729-734

  Karabulut, A A ^a,c   Serel, B Izol ^b   Eksioglu, H M ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c NONE   (Turkey)

Author keywords

Pimecrolimus; Rosacea; Topical calcineurin inhibitor; Treatment

Indexed keywords

PIMECROLIMUS; PLACEBO; SUNSCREEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EMOTIONAL STRESS; ENVIRONMENTAL TEMPERATURE; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; LIP DISEASE; MALE; MENSTRUATION; PAPULE; PAPULOPUSTULAR ROSACEA; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; ROSACEA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN SENSATION; SUN; TELANGIECTASIA; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADULT; DERMATOLOGIC AGENTS; FACE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PLACEBOS; ROSACEA; SINGLE-BLIND METHOD; TACROLIMUS;

EID: 43649090624     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02589.x     Document Type: Article

References (22)

1. Wilkin J, Dahl M, Detmar M et al.; National Rosacea Society Expert Committee. Standard grading system for rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2004; 50: 907-912.
2. Crawford GH, Pelle MT, James WD, Rosacea I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-341.
3. Gupta AK, Chaundry MM. Rosacea and its management: An overview. J Eur Acad Dermatol 2005; 19: 273-285.
4. Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J Am Acad Dermatol 2007; 56: 107-115.
5. Heymann WR. Rosacea subtype-directed therapy. J Am Acad Dermatol 2004; 51: 91-92.
6. Pelle MT, Crawford GH, James WD, Rosacea. II. Therapy. J Am Acad Dermatol 2004; 51: 499-512.
7. Yazici AC, Tamer L, Ikizoglu G et al. GSTM1 and GSTT1 null genotypes as possible heritable factors of rosacea. Photodermatol Photoimmunol Photomed 2006; 22: 208-210.
8. Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus an anti-inflammatory drug targeting skin. Exp Dermatol 2004; 13: 721-730.
9. Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol 2007; 8: 157-173.
10. Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed 2005; 4: 147-150.
11. Cunha PR, Rossi AB. Pimecrolimus cream 1% is effective in a case of granulomatous rosacea. Acta Derm Venereol 2006; 86: 71-72.
12. Meykadeh N, Meiss F, Marsch WC, Fischer M. Steroidaggravierte rosazea: erfolgreiche therapie mit pimecrolimus. Hautarzt 2007; 58: 338-342.
13. Weissenbacher S, Merkl J, Hildebrandt B et.al. Pimecrolimus cream 1% for papulopustular rosacea: A randomized vehicle-controlled double-blind trial. Br J Dermatol 2007; 156: 728-732.
14. Long CC, Finlay AY. The finger-tip unit - a new practical measure. Clin Exp Dermatol 1991; 16: 444-447.
15. El Sayed F, Ammoury A, Dhaybi R, Bazex J. Rosaceiform eruption to pimecrolimus. J Am Acad Dermatol 2006; 54: 548-550.
16. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: A preliminary report. J Am Acad Dermatol 2001; 44: 995-998.
17. Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol 2004; 50: 107-108.
18. Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005; 152: 396-399.
19. Chu CY. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption. J Eur Acad Dermatol Venereol 2007; 21: 484-490.
20. Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 2004; 140: 457-460.
21. Lübbe J, Stucky L, Saurat JH. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology 2003; 207: 204-205.
22. Van Leent EJ, De Vries HJ, Ebelin ME, Burtin P, Scott G, Bos JD Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. J Dermatolog Treat 2007; 18: 19-22.